Slayback Pharma Appoints Joan Janulis as Head of Global Regulatory Affairs

PRINCETON, N.J., July 16, 2018 /PRNewswire/ -- Slayback Pharma LLC ("Slayback"), a privately held pharmaceutical research and development company, announced today the appointment of Joan Janulis as the Senior Vice President of Global Regulatory Affairs.

Ms Janulis is a highly accomplished Regulatory Affairs leader with extensive knowledge of the US FDA regulations and best practices and a stellar track record on both the generic pharma as well as the 505b2 side. She served a long innings of 11 years with Lachman Consultants, a premier pharmaceutical consulting company, where she was the Vice President and Head of the Regulatory Practice and also served on Lachman's Board of Directors. Ms. Janulis has held various executive positions at Vensun, Faulding/Purepac Pharmaceutical (now Actavis), Ivax Pharmaceuticals (now Teva), and Able Laboratories. Ms Janulis is also a noted speaker at various FDA/Industry conferences, including GPhA, ISPE etc.

While welcoming Joan to Slayback, Ajay Singh, President & CEO, said, "I am really delighted to have Joan Janulis join the Slayback leadership team as Senior Vice President and Head of Global Regulatory Affairs. Her vast experience and knowledge of FDA regulations will be immensely useful to Slayback in the strategy, filing and approval of both complex generics and its innovative 505b2 pipeline."

"I am very excited to be joining Slayback and truly look forward to working collaboratively with such a seasoned and motivated team," said Ms Janulis.

ABOUT SLAYBACK PHARMA LLC
Slayback is a New-Jersey based pharmaceutical company focused on the development of complex generic and specialty pharmaceutical products.

SOURCE Slayback Pharma LLC